Tempest Therapeutics (TPST) Operating Leases (2019 - 2026)

Tempest Therapeutics has reported Operating Leases for 7 years, with the latest figure at $6.9 million in Q4 2025.

• Quarterly Operating Leases fell 14.65% year-over-year to $6.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.9 million (down 14.65% YoY) and the FY2025 annual result came in at $6.9 million, down 14.65% from the prior year.
• Operating Leases fell to $6.9 million in Q4 2025 per TPST's latest filing, from $7.3 million in the prior quarter.
• Over five years, Operating Leases peaked at $10.3 million in Q4 2022 and troughed at $503000.0 in Q3 2022.
• A 5-year average of $6.3 million and a median of $7.7 million in 2025 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2023: Operating Leases slumped 79.02% in 2022, then surged 1765.61% in 2023.
• Over 5 years, Operating Leases stood at $2.0 million in 2021, then soared by 409.87% to $10.3 million in 2022, then fell by 11.33% to $9.2 million in 2023, then declined by 11.11% to $8.1 million in 2024, then dropped by 14.65% to $6.9 million in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $6.9 million, $7.3 million, and $7.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.